Active Biotech AB Interim Report January – September 2013

Nov 7, 2013 08:30 (CET)
Laquinimod
  • Analysis of data from the Phase III ALLEGRO study shows that laquinimod provides a beneficial impact on brain tissue damage; Laquinimod-treated patients accumulated significantly less brain tissue damage caused by neurodegeneration
  • New data presented at ECTRIMS shows that laquinimod has an effect on both inflammation and the underlying mechanisms associated with disease progression in multiple sclerosis
  • Teva is planning to commence clinical trials in Huntington’s disease and primary progressive multiple sclerosis (PPMS)
  • Teva will initiate a further clinical trial in multiple sclerosis (LIBRETTO)                  

Tasquinimod      

  • Phase III 10TASQ10 study is proceeding as planned; the primary analysis of progression-free survival (PFS) and survival (OS) is expected in 2014
  • Active Biotech received a milestone payment of EUR 12 M from Ipsen                    

ANYARA     

  • Detailed analysis provides further support for ANYARA’s efficacy in a biomarker-defined sub-group of renal cell cancer patients; the result from the Phase II/III study was presented at the 2013 European Cancer Congress 

Paquinimod (57-57)             

  • Evaluation under way of clinical trial in systemic sclerosis

ISI    

  • Project proceeding according to plan

     
Financial summary   
   

SEK M                          Q3                    Jan – Sept          Jan – Dec
    2013 2012   2013 2012   2012
                 
Net sales   107.0 39.8   111.9 136.4   227.9
                 
Operating loss   27.9 -48.2   -128.6 -168.7   -163.2
                 
Profit/Loss after tax   29.2 -51.6   -130.0 -175.1   -175.0
                 
Profit/loss per share   0.39 -0.75   -1.77 -2.54   -2.54

For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95                                      

Hans Kolam, CFO                                                               
Tel: +46 (0)46-19 20 44                                                      

Active Biotech AB(Corp. Reg. No. 556223-9227)
Box 724, 220 07 Lund
Tel: +46 (0)46-19 20 00
Fax +46 (0)46-19 11 00

The report is also available at www.activebiotech.com               
       

Active Biotech AB Interim Report January – September 2013

—
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Active Biotech via Thomson Reuters ONE
HUG#1741192